Cytokinetics, Inc. (NASDAQ:CYTK) has been given a consensus rating of “Buy” by the thirteen research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $16.78.
A number of equities research analysts recently issued reports on CYTK shares. HC Wainwright set a $20.00 target price on Cytokinetics and gave the company a “buy” rating in a research report on Friday, January 19th. Morgan Stanley reissued an “overweight” rating and issued a $17.00 target price (down previously from $25.00) on shares of Cytokinetics in a research report on Wednesday, November 22nd. Cantor Fitzgerald lowered Cytokinetics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $21.00 to $10.00 in a research report on Wednesday, November 22nd. ValuEngine lowered Cytokinetics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 21st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Cytokinetics in a research report on Sunday, October 29th.
A number of hedge funds have recently bought and sold shares of CYTK. Virtu Financial LLC bought a new position in Cytokinetics in the fourth quarter valued at approximately $112,000. Teacher Retirement System of Texas bought a new position in shares of Cytokinetics during the 4th quarter worth approximately $113,000. Ellington Management Group LLC bought a new position in shares of Cytokinetics during the 4th quarter worth approximately $128,000. Birchview Capital LP bought a new position in shares of Cytokinetics during the 3rd quarter worth approximately $145,000. Finally, Granite Investment Advisors LLC bought a new position in shares of Cytokinetics during the 4th quarter worth approximately $151,000. Hedge funds and other institutional investors own 63.67% of the company’s stock.
Shares of Cytokinetics (NASDAQ CYTK) traded down $0.27 during trading on Wednesday, reaching $7.75. The company had a trading volume of 422,600 shares, compared to its average volume of 367,075. Cytokinetics has a 1-year low of $7.00 and a 1-year high of $17.20. The firm has a market cap of $424.34, a price-to-earnings ratio of -3.05 and a beta of 1.03. The company has a debt-to-equity ratio of 0.29, a quick ratio of 7.60 and a current ratio of 8.46.
Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.04). Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 96.95%. The firm had revenue of ($0.02) million during the quarter, compared to analyst estimates of $4.83 million. analysts anticipate that Cytokinetics will post -1.74 EPS for the current fiscal year.
WARNING: “Cytokinetics, Inc. (CYTK) Given Average Rating of “Buy” by Brokerages” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/21/cytokinetics-inc-cytk-given-average-rating-of-buy-by-brokerages.html.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.